Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine 2001 March;45(1) > The Quarterly Journal of Nuclear Medicine 2001 March;45(1):27-37

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

  NUCLEAR MEDICINE APPLICATIONS FOR BONE METASTASES 

The Quarterly Journal of Nuclear Medicine 2001 March;45(1):27-37

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions

Savelli G., Maffioli L. *, Maccauro M., De Deckere E. **, Bombardieri E.

From the Division of Nuclear Medicine Istituto Nazionale Tumori, Milano, Italy *Division of Nuclear Medicine Ospedale Generale, Lecco, Italy **Division of Nuclear Medicine Leiden University Medical Centre, Leiden, The Netherlands


PDF


Skeletal metas­ta­ses are one of the ­major clin­i­cal prob­lems for the oncol­o­gist. Over the ­last sev­er­al ­decades ­bone scin­tig­ra­phy has ­been ­used exten­sive­ly in detect­ing ­bone involve­ment ­since it can pro­vide infor­ma­tion ­about dis­ease loca­tion, prog­no­sis and the effec­tive­ness of treat­ment. Bone ­scan ­offers the advan­tage of ­total ­body exam­ina­tion, and imag­es ­bone ­lesions ear­lier ­than oth­er tech­niques. In ­this ­paper the ­main clin­i­cal prob­lems relat­ed to the ­most com­mon appli­ca­tions of ­bone ­scan in ­breast, pros­tate, ­lung can­cer and oth­er ­tumours are dis­cussed. The expe­ri­ence car­ried out at the National Cancer Institute of Milan by ­using ­bone ­SPECT to ­detect sin­gle ­bone metas­ta­ses is report­ed. One hundred and eighteen ­patients ­with ­bone metas­ta­ses (­from dif­fer­ent ­tumour ­types: ­breast, ­lung, pros­tate, lym­pho­mas, etc.) ­were stud­ied by pla­nar scin­tig­ra­phy, ­SPECT and oth­er radio­log­i­cal modal­ities (CT, MRI or X-­rays). The over­all per­for­manc­es of ­bone ­SPECT ­were sen­si­tiv­ity: 90.5% (19/21), spec­i­fic­ity 92.8% (90/97), pos­i­tive pre­dic­tive val­ue 73% (19/26), neg­a­tive pre­dic­tive val­ue 97.8% (90/92), accu­ra­cy 92.4% (109/118). Considering ­breast can­cer, the ­most fre­quent pathol­o­gy in our ­series, and the lum­bar spi­nal ­tract, the ­most com­mon skel­e­tal seg­ment ­involved, the fig­ures of mer­it of ­SPECT ­were: sen­si­tiv­ity 100% (4/4), spec­i­fic­ity 95.3% (41/43), pos­i­tive pre­dic­tive val­ue 66.7% (4/6), neg­a­tive pre­dic­tive val­ue 100% (41/41), accu­ra­cy 95.7% (45/47). In con­clu­sion ­bone ­SPECT ­showed ­very ­good per­for­manc­es, in par­tic­u­lar improv­ing the pre­dic­tive val­ue of pla­nar ­scan in the diag­no­sis of ver­te­bral metas­ta­ses.

top of page